Prior to the availability of eculizumab, the prognosis of patients with atypical haemolytic uraemic syndrome was poor.
There was a high rate of patients developing kidney failure and and recurrent disease in renal transplants was common.
The availability of complement inhibition has transformed outcomes for patients with atypical haemolytic uraemic syndrome.
The introduction of eculizumab, a monoclonal antibody against C5 controls disease in many patients and prevents the development of end-stage renal failure.
